Medulloblastoma is the most common malignant brain tumor in children, arising in the cerebellum, the part of the brain that controls balance and coordination. It accounts for roughly 20 percent of all childhood brain tumors and tends to strike between ages three and eight, though it can appear in adolescents and, less commonly, adults. Over the past two decades, molecular profiling has fundamentally reshaped how doctors understand and treat the disease, revealing that “medulloblastoma” is not one cancer but at least four distinct diseases bundled under a single name.
Where It Starts and Why the Cerebellum
The cerebellum sits at the back of the brain, just above the brainstem. During childhood, it is still actively developing, and that developmental activity is part of what makes it vulnerable. Medulloblastoma arises from immature nerve cells that are still dividing. Research in mouse models has shown that tumors driven by the Sonic Hedgehog signaling pathway can be initiated in either committed nerve-cell progenitors or in stem cells, though tumors starting in stem cells tend to develop faster and more aggressively.
A key insight from developmental biology is that the tumor seems to require commitment to a specific cell lineage. Studies have found that activation of Hedgehog signaling in a range of early and late brain progenitors all produced medulloblastoma rather than other types of brain cancer, suggesting that something about becoming a cerebellar granule neuron precursor is essential for this tumor to form.1Cancer Cell. Sonic Hedgehog-Regulated Lineage-Restricted Progenitors Contribute to Medulloblastoma Pathogenesis In other words, the cancer does not simply arise from any brain cell gone wrong. It hijacks a very specific developmental program.
Four Molecular Subgroups, Four Different Diseases
The 2021 WHO classification of central nervous system tumors cemented what researchers had been pushing toward for years: medulloblastoma should be classified by its molecular profile, not just how it looks under a microscope.2PubMed Central. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary The four recognized subgroups are WNT, SHH (Sonic Hedgehog), Group 3, and Group 4. Each has a different biology, a different patient profile, and a dramatically different prognosis.
WNT tumors are the rarest subgroup but carry the best outlook. In children aged three to sixteen enrolled in a major clinical trial, WNT patients had significantly better survival than those with SHH or non-SHH/WNT tumors.3PubMed Central. Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups Most WNT tumors have a classic appearance under the microscope and frequently show a specific chromosomal abnormality, loss of one copy of chromosome 6. Because outcomes are so favorable, some current trials are actually testing whether treatment intensity can be safely reduced for WNT patients to spare them long-term side effects.
SHH tumors are driven by overactivation of the Sonic Hedgehog pathway. They account for roughly a third of all medulloblastomas and are the dominant subtype in infants and adults, with a relative dip in school-age children. The specific genetic mutation within the SHH pathway varies by age: infants tend to carry mutations in a gene called SUFU (sometimes inherited), adults more often have mutations in SMO, and school-age children are more likely to harbor downstream amplifications of MYCN or GLI2 along with TP53 mutations.4PubMed Central. Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition That last combination, SHH plus a TP53 mutation, defines an extremely high-risk group with poor survival rates.5PubMed Central. p53 and Medulloblastoma
Group 3 tumors are the most aggressive. They occur predominantly in young children, are frequently metastatic at diagnosis, and often carry amplification of the MYC gene. MYC amplification is associated with rapid, widespread spread beyond the brain, including to bone marrow, liver, and lymph nodes.6PubMed Central. Fulminant extraneural metastases in MYC-amplified Group 3 medulloblastoma: a pediatric case report Research into how MYC-driven cells promote metastasis has identified a molecule called lactate dehydrogenase A (LDHA) that helps tumor cells seed and grow at distant sites, and early lab work suggests targeting LDHA can suppress tumor cell migration.7Neuro-Oncology. Intratumoral heterogeneity of MYC drives medulloblastoma metastasis and angiogenesis
Group 4 is the most common subgroup overall but paradoxically the least well understood. It tends to appear in older children and adolescents. Its molecular drivers remain somewhat elusive, though recent work points to a protein called PRDM6 as one contributor. Interestingly, when PRDM6 was expressed in stem cells in lab models, the resulting tumors matched Group 3 rather than Group 4, suggesting that Group 4 likely requires additional factors or a very specific cell of origin.8PubMed Central. PRDM6 promotes medulloblastoma by repressing chromatin accessibility and altering gene expression
How Medulloblastoma Is Found and Staged
Most children with medulloblastoma arrive at the hospital because of symptoms caused by the tumor blocking the flow of cerebrospinal fluid: headaches, nausea, vomiting, and balance problems that get worse over days to weeks. An MRI of the brain typically reveals a mass in the posterior fossa, the space at the back of the skull that houses the cerebellum.
Imaging is not just for finding the primary tumor. Because medulloblastoma has a strong tendency to spread along the lining of the brain and spinal cord, staging requires a full spinal MRI to check for these so-called leptomeningeal metastases.9PubMed. Magnetic Resonance Imaging in the Contemporary Management of Medulloblastoma: Current and Emerging Applications Radiologists are increasingly able to predict the molecular subgroup from imaging features alone. SHH tumors tend to sit at the edges of the cerebellum, WNT tumors favor the cerebellopontine angle, Group 4 tumors often show minimal contrast enhancement, and Group 3 tumors are more likely to present with spinal metastases at diagnosis.10American Journal of Neuroradiology. MRI Characteristics of Primary Tumors and Metastatic Lesions in Molecular Subgroups of Pediatric Medulloblastoma: A Single-Center Study These imaging clues can help guide early treatment decisions even before the molecular results come back from the pathology lab.
Surgery and the Tradeoff of Aggressive Resection
Surgery is almost always the first step. The goal is to remove as much of the tumor as possible while preserving brain function. Modern surgical techniques have dramatically improved the rate of complete or near-complete removal: one study found the proportion of patients with no visible residual tumor on post-operative imaging climbed from about 77 percent in the 1990s to 94 percent by the 2000s.11PubMed. Incidence, risks, and sequelae of posterior fossa syndrome in pediatric medulloblastoma
But that improvement came at a cost. More aggressive resection was associated with a higher incidence of posterior fossa syndrome, a complication where children lose the ability to speak, develop severe balance problems, and show emotional changes in the days following surgery. The same study found that as the rate of complete resection went up, so did the rate of posterior fossa syndrome, climbing from about 17 percent to 39 percent. Most children eventually recover speech and motor function, but recovery can take months and may not be complete. It is one of the most distressing complications for families to witness.
Radiation and the Proton Advantage
After surgery, most patients over three years old receive craniospinal irradiation, meaning the entire brain and spinal cord are treated with radiation. This is because medulloblastoma seeds microscopically along the neuraxis even when no visible metastases are detected. The posterior fossa then gets an additional “boost” dose. While radiation has been central to curing medulloblastoma for decades, it comes with significant long-term costs, especially in developing brains.
Proton beam therapy has emerged as a meaningful improvement over traditional photon (X-ray) radiation. Protons deposit their energy more precisely and largely stop at the tumor target rather than passing through to organs beyond. In adults, proton craniospinal irradiation delivered essentially zero dose to the heart, compared with a mean heart dose above 14 Gy with photon treatment. Patients treated with photons had significantly higher rates of difficulty swallowing and lost weight during treatment, while proton patients actually gained a small amount of weight on average.12Neuro-Oncology Advances. Proton versus photon craniospinal irradiation for adult medulloblastoma: A dosimetric, toxicity, and exploratory cost analysis
In children, a systematic review of proton versus photon studies reported that proton-treated patients had lower rates of thyroid problems (about 23 percent versus 69 percent with photons), lower rates of sex hormone deficiency (roughly 3 percent versus 19 percent), greater height preservation, and fewer acute side effects.13PubMed Central. Proton Radiotherapy for Management of Medulloblastoma: A Systematic Review of Clinical Outcomes These differences are substantial and affect quality of life for years or decades after treatment.
Chemotherapy and the Special Case of Infants
Chemotherapy is a standard part of treatment for almost all medulloblastoma patients. In average-risk children, a combination of drugs is typically given after radiation. In high-risk patients, chemotherapy regimens tend to be more intensive. The specific drugs used have remained relatively stable for years, though their sequencing and dosing continue to be refined through clinical trials.
For infants and very young children, the stakes are different. Radiation to a developing brain under age three causes devastating cognitive damage. To avoid or delay radiation, some protocols use high-dose chemotherapy followed by autologous stem cell rescue, a procedure where a child’s own stem cells are collected before intensive chemotherapy and then returned to rebuild the bone marrow afterward.14PubMed Central. High-dose chemotherapy with autologous stem cell rescue in children under 5 years of age with central nervous system embryonal tumors: results from a prospective cohort in an upper-middle-income country This approach can spare very young children from the worst neurocognitive consequences of radiation, though outcomes vary considerably depending on the tumor’s molecular subgroup.
Targeted Therapies for the SHH Subgroup
The SHH subgroup has attracted the most attention from drug developers because its driving pathway is well characterized and, at least in theory, druggable. Vismodegib and sonidegib are oral medications that block the Smoothened (SMO) protein, a critical relay station in the Hedgehog pathway. Both drugs are approved for basal cell carcinoma in adults and have been tested in medulloblastoma clinical trials.
The catch is that these drugs work best when the tumor’s mutation sits “upstream” in the pathway, at the level of SMO or the receptor PTCH1. When the mutation sits further downstream, as it often does in school-age children with MYCN or GLI2 amplifications, the drugs are less effective because the signal has already bypassed the point where the drug intervenes. Age-related mutational patterns therefore directly predict who is likely to benefit.
Resistance is another hurdle. Tumors can develop mutations that physically prevent the drug from binding to SMO, or they can lose structures called primary cilia, which are normally needed for Hedgehog signaling but whose absence allows the tumor to maintain low-level pathway activity even when the drug is present.15PubMed Central. Phase I and phase II sonidegib and vismodegib clinical trials for the treatment of paediatric and adult MB patients: a systemic review and meta-analysis Laboratory studies have shown that activating a cellular energy sensor called AMPK, using drugs like metformin, can resensitize resistant tumors to vismodegib and suppress tumor growth when combined with it.16PubMed Central. Activation of AMPK sensitizes medulloblastoma to Vismodegib and overcomes Vismodegib-resistance Whether that combination will translate to patients remains to be seen, but it illustrates the kind of creative workaround researchers are pursuing.
The Long Aftermath of Cure
Survival rates for medulloblastoma have improved dramatically over the past several decades. For standard-risk patients, five-year survival now exceeds 70 to 80 percent in many treatment centers, and WNT-subgroup patients do even better. But survival often comes at a steep price in quality of life.
A study assessing long-term survivors found that 75 percent had hypothyroidism, 25 percent had growth hormone deficiency, and 25 percent had sex hormone disorders. The neuropsychiatric toll was even heavier: 90 percent of survivors had psychiatric issues, 55 percent had neurological problems, and 70 percent had two or more neuropsychiatric problems at the same time.17PubMed. Late effects of medulloblastoma treatment: multidisciplinary approach of survivors Reviews of cognitive outcomes consistently identify slowing of processing speed, difficulties with attention, and working memory problems as the core deficits, largely driven by radiation damage to white matter and cerebellar injury from the tumor itself or from surgery.18Neuro-Oncology Practice. Core deficits and quality of survival after childhood medulloblastoma: a review
There is also the risk of developing a second cancer years later. A Children’s Oncology Group trial estimated a cumulative ten-year incidence of secondary malignancies of about 4 percent, with most being high-grade brain tumors that appeared more than five years after the original diagnosis. All non-brain secondary solid tumors occurred in regions that had received radiation.19PubMed Central. Survival and secondary tumors in children with medulloblastoma receiving radiotherapy and adjuvant chemotherapy: results of Children’s Oncology Group trial A9961 A separate comparison of proton and photon patients found similar overall rates of secondary tumors between the two radiation types, though the locations of the secondary cancers differed depending on the beam path.20PubMed. Overall survival and secondary malignant neoplasms in children receiving passively scattered proton or photon craniospinal irradiation for medulloblastoma With more children surviving, managing these late effects over a lifetime is becoming as important as curing the cancer in the first place.
Inherited Risk and Cancer Predisposition Syndromes
Most cases of medulloblastoma arise without a clear inherited cause, but a meaningful minority are linked to cancer predisposition syndromes. The best-known example is Gorlin syndrome (also called basal cell nevus syndrome), caused by inherited mutations in the PTCH1 gene. People with Gorlin syndrome are predisposed to basal cell carcinomas of the skin and to SHH-subgroup medulloblastoma, typically in infancy.21PubMed Central. Cancer Predisposition Syndromes and Medulloblastoma in the Molecular Era Lab models using stem cells from Gorlin syndrome patients have confirmed that these cells can form medulloblastoma when transplanted into the brain, underscoring how directly the inherited mutation contributes to tumor formation.22Cell Stem Cell. Human Stem Cell-Based Models of Sonic Hedgehog Medulloblastoma Dictate the Efficacy of Cooperating Genetic Events
Li-Fraumeni syndrome, caused by germline TP53 mutations, is another key predisposition. Children with Li-Fraumeni who develop SHH medulloblastoma face the worst prognosis of almost any medulloblastoma subtype. Other syndromes linked to medulloblastoma include Turcot syndrome (associated with mutations in the APC gene) and familial adenomatous polyposis, both connected to the WNT pathway. Genetic counseling and germline testing are now increasingly standard parts of the diagnostic workup, especially for very young patients and those with SHH tumors.
The Immune Landscape and Why Immunotherapy Is Hard
Medulloblastoma is generally considered an immunologically “cold” tumor, meaning it attracts relatively few immune cells and has an intact blood-brain barrier that further limits immune access.23PubMed. Single-cell deconstruction of medulloblastoma microenvironment elucidates subtype-specific immune architectures and prognostic molecular signatures But the picture varies sharply by subgroup. WNT tumors tend to contain microglia-derived immune cells with anti-tumor properties, while SHH, Group 3, and Group 4 tumors are dominated by tumor-associated macrophages that suppress immune responses and by exhausted T cells that have essentially stopped fighting. High counts of a type of macrophage called M2 have been linked to worse short-term prognosis, consistent with their known role in promoting tumor growth and dampening inflammation.24The Lancet. Spatially resolved immune profiling of paediatric medulloblastoma reveals prognostic significance of immune infiltration and B cells
This immunosuppressive environment is one reason checkpoint inhibitors, which have transformed treatment for many adult cancers, have not shown the same promise in medulloblastoma. The immune system is not just failing to attack the tumor; the tumor is actively disarming it.
CAR T Cells and the Question of Delivery
Engineered immune cells called CAR T cells represent one of the more promising experimental approaches, particularly for Group 3 tumors that currently lack targeted drug options. Researchers have shown that CAR T cells designed to recognize targets such as EPHA2, HER2, and IL13Rα2 can effectively treat primary, metastatic, and recurrent Group 3 medulloblastoma in mouse models when delivered directly into the cerebrospinal fluid rather than through the bloodstream.25PubMed Central. Locoregional delivery of CAR T-cells to the cerebrospinal fluid for treatment of metastatic medulloblastoma and ependymoma That delivery route matters because the blood-brain barrier prevents most immune cells from reaching the tumor when infused intravenously.
More recent work has focused on refining which target antigen works best and whether genetic modifications to the CAR T cells themselves can boost their persistence. In comparisons between different targets, EphA2-directed CAR T cells showed superior tumor control over B7-H3-directed cells across multiple Group 3 models. Genetic engineering that added a cytokine-boosting signal to the CAR T cells extended their activity, with some mice achieving long-term remission beyond 100 days.26PubMed Central. Antigen Specificity and Cell Engineering Determine CAR T Cell Efficacy in Group 3 Medulloblastoma These are still animal studies, but they form the basis for clinical trials that are beginning to enroll patients.
Liquid Biopsies and Monitoring Without Surgery
One of the practical headaches of managing medulloblastoma is monitoring for relapse. Brain MRIs are done regularly after treatment, but they can be ambiguous, and by the time a scan clearly shows recurrence, the disease may already be advanced. Researchers have been exploring whether tumor DNA floating in the cerebrospinal fluid (called circulating tumor DNA, or ctDNA) can detect disease earlier and with less ambiguity.
A study published in Nature Communications found that ctDNA was detectable in the cerebrospinal fluid but barely present in the blood of medulloblastoma patients. The CSF ctDNA reflected the genomic profile of the tumor well enough to classify it by molecular subgroup and to identify minimal residual disease, meaning tiny amounts of cancer remaining after treatment that had not yet appeared on imaging.27PubMed Central. Circulating tumour DNA from the cerebrospinal fluid allows the characterisation and monitoring of medulloblastoma A separate study used methylation profiling of CSF cell-free DNA and similarly found it could detect tumor occurrence, determine subtype, and track treatment response and recurrence over time.28PubMed Central. Reliable tumor detection by whole-genome methylation sequencing of cell-free DNA in cerebrospinal fluid of pediatric medulloblastoma
The limitation is that collecting CSF still requires a lumbar puncture, which is not trivial. But compared to a second brain surgery to biopsy a suspicious lesion, it is far less invasive. If validated in larger studies, CSF-based liquid biopsies could change how patients are monitored during and after treatment, catching recurrence sooner and potentially guiding treatment changes before the disease has time to gain momentum.
Adults With Medulloblastoma
While medulloblastoma is primarily a pediatric disease, it does occur in adults, and the experience differs in several important ways. Adults are more likely to have SHH-subgroup tumors, and the genetic features within that subgroup differ from those seen in children. A large study of adult medulloblastoma reported unique cytogenetic features across subgroups that were distinct from pediatric patients and that correlated with survival differences.29Acta Neuropathologica. Subgroup and subtype-specific outcomes in adult medulloblastoma
Treatment protocols for adults are often adapted from pediatric regimens because there is far less clinical trial data in adults. The disease is rare enough in the adult population that dedicated large-scale trials are difficult to run. Adults also tend to tolerate craniospinal irradiation differently, with more acute side effects during treatment, making the proton versus photon choice even more consequential. And the survivorship challenges, particularly cognitive decline and hormonal disruption, play out against the backdrop of careers, relationships, and independence in ways that differ from a child’s experience. The relative scarcity of data and adult-specific guidance remains one of the field’s more frustrating gaps.